Metabolic & Endocrine
Diabetic Macular Oedema
0
Pipeline Programs↗
1
Active Trials↗
3
Companies Involved↗
Diabetic Macular Oedema is an early-stage landscape with 0 programs across 3 companies. The most active players are AbbVie, Novartis, Bayer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
19
clinical trials
Completed14 · 74%
Terminated3 · 16%
Recruiting1 · 5%
Withdrawn1 · 5%
Clinical Trials
Trial Activity
19 trials
Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema
Recruiting·—·Phase 4·NCT04910503·106 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)